In two landmark studies [131,132], Lindsay et al. demonstrated that the systemic administration of AdV vectors expressing mouse IL-10 reduces clinical and histological signs of 2,4,6-trinitrobenzene sulphonic acid (TNBS) colitis, the murine model for inflammatory bowel diseases known to be poorly responsive to systemic injections of recombinant IL-10. Here, IL10 is linked to colitis.